Sector Watch: Healthcare - Mar 20 2019
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $113.11 -0.74 -0.65% | XBI: $90.44 -0.80 -0.88% | Updated Mar 20, 2019 04:00 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| NVRO Nevro $1.8B |
60.73+15.96 6.9 M 13.6x |
36% | ||
| PFNX Pfenex $193.0M |
6.18+1.03 279.8 K 2.2x |
20% | ||
| CYTK52WH Cytokinetics $564.3M |
10.27+1.71 2.2 M 3.5x |
20% | ||
| NVAX Novavax $246.6M |
0.64+0.09 54.3 M 2.6x |
17% | ||
| CFMS52WH ConforMIS $169.1M |
2.49+0.35 2.4 M 2.2x |
16% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| BIOS52WL BioScrip $273.3M |
2.13-0.28 3.1 M 2.2x |
-12% | ||
| LQDA Liquidia Technologies $213.6M |
13.72-1.49 100.4 K 1.7x |
-10% | ||
| CSU Capital Senior Living $140.5M |
4.48-0.47 240.0 K |
-9% | ||
| SRNE Sorrento Therapeutics $428.0M |
3.50-0.34 3.8 M 1.8x |
-9% | ||
| ICAD Icad $72.4M |
4.20-0.40 68.1 K |
-9% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis [globenewswire.com]Liquidia Technologies Announces Proposed Offering of Common Stock [globenewswire.com]
Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference [globenewswire.com]
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results [globenewswire.com]
iCAD Reports Fourth Quarter and Full-Year 2018 Financial Results [globenewswire.com]
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19 [globenewswire.com]
Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer - GlobeNewswire (0 visits) [globenewswire.com]
BioScrip Reports Fourth Quarter and Full Year 2018 Financial Results [globenewswire.com]
Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge [globenewswire.com]
iCAD to Present Corporate Overview at the 31st Annual ROTH Conference [globenewswire.com]
BioScrip Reschedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call [globenewswire.com]
iCAD to Report Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results on Monday, March 18 [globenewswire.com]
The 3D designed Conformis Hip System Announced at the 2019 AAOS conference [globenewswire.com]
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019 [globenewswire.com]
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update [globenewswire.com]
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19 [globenewswire.com]
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001 [globenewswire.com]
Liquidia?s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
